NASDAQ:GANX

Gain Therapeutics Stock Forecast, Price & News

$13.20

-0.80 (-5.71 %)

(As of 04/13/2021 12:00 AM ET)

Add

Compare

Today's Range

$13.00

Now: $13.20▼

$14.00

50-Day Range N/A

52-Week Range

$11.00

Now: $13.20▼

$17.93

Volume62,113 shs

Average Volume171,225 shs

Market Capitalization$149.57 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:GANX

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.gaintherapeutics.com

Phone301-500-1556

EmployeesN/A

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares11,331,000

Market Cap$149.57 million

Next Earnings DateN/A

OptionableNot Optionable

Headlines

Why Gain Therapeutics's Stock is Up During Today's Session
April 12, 2021 | msn.com

Oppenheimer Initiates Coverage on Gain Therapeutics (NASDAQ:GANX)
April 12, 2021 | americanbankingnews.com

Gain Therapeutics (NASDAQ:GANX) Earns Buy Rating from Analysts at BTIG Research
April 12, 2021 | americanbankingnews.com

Gain Therapeutics (NASDAQ:GANX) Trading Down 0.1%
April 10, 2021 | americanbankingnews.com

Gain Therapeutics Inc
March 31, 2021 | reuters.com

Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option to Purchase Additional Shares
March 31, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.70 out of 5 stars

Medical Sector

259th out of 2,019 stocks

Biotechnology Industry

20th out of 145 stocks

3.5 Analyst's Opinion

Consensus Rating
Gain Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.00, Gain Therapeutics has a forecasted upside of 127.3% from its current price of $13.20.
Amount of Analyst Coverage
Gain Therapeutics has only been the subject of 2 research reports in the past 90 days.

5.0 Community Rank

Outperform Votes
Gain Therapeutics has received 2 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Gain Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Gain Therapeutics has received 100.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Gain Therapeutics and other stocks. Vote “Outperform” if you believe GANX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GANX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Gain Therapeutics does not currently pay a dividend.
Dividend Growth
Gain Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gain Therapeutics insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$13.20

-0.80 (-5.71 %)

(As of 04/13/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive GANX News and Ratings via Email

Sign-up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter.

Gain Therapeutics (NASDAQ:GANX) Frequently Asked Questions

Is Gain Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gain Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Gain Therapeutics stock.
View analyst ratings for Gain Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Gain Therapeutics?

Wall Street analysts have given Gain Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gain Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for GANX?

2 Wall Street analysts have issued 12 month target prices for Gain Therapeutics' stock. Their forecasts range from $30.00 to $30.00. On average, they anticipate Gain Therapeutics' stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 127.3% from the stock's current price.
View analysts' price targets for Gain Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Gain Therapeutics' key executives?

Gain Therapeutics' management team includes the following people:

Dr. Khalid Islam, Founder & Chairman (Age 66)
Mr. Eric I. Richman M.B.A., CEO & Director (Age 60)
Dr. Manolo Bellotto Ph.D., Pres & GM (Age 50)
Mr. Salvatore Calabrese, Chief Financial Officer (Age 51)
Mr. Xavier Barril, Chief Scientific Officer
Dr. Ana Maria Garcia-Collazo Ph.D., Head of Research
Dr. Elena Cubero-Jorda Ph.D., Head of Computational Modeling
Dr. Natalia Perez-Carmona Ph.D., Head of Biology
Mr. Roberto Maj Pharm.D., Head of Devel.

Who are some of Gain Therapeutics' key competitors?

Some companies that are related to Gain Therapeutics include Biotest Aktiengesellschaft (BIO), Sigilon Therapeutics (SGTX), Aptose Biosciences (APS), Inventiva (IVA), Ergomed (ERGO), 22nd Century Group (XXII), Burcon NutraScience (BU), Gemini Therapeutics (GMTX), NexImmune (NEXI), Silence Therapeutics (SLN), Theratechnologies (TH), Terns Pharmaceuticals (TERN), Sensei Biotherapeutics (SNSE), Pfenex (PFNX) and BELLUS Health (BLU).
View all of GANX's competitors.

When did Gain Therapeutics IPO?

(GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager.

What is Gain Therapeutics' stock symbol?

Gain Therapeutics trades on the NASDAQ under the ticker symbol "GANX."

When does the company's quiet period expire?

Gain Therapeutics' quiet period expires on Tuesday, April 27th. Gain Therapeutics had issued 3,636,364 shares in its public offering on March 18th. The total size of the offering was $40,000,004 based on an initial share price of $11.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Gain Therapeutics?

Shares of GANX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gain Therapeutics' stock price today?

One share of GANX stock can currently be purchased for approximately $13.20.

How much money does Gain Therapeutics make?

Gain Therapeutics has a market capitalization of $149.57 million.

What is Gain Therapeutics' official website?

The official website for Gain Therapeutics is www.gaintherapeutics.com.

How can I contact Gain Therapeutics?

The company can be reached via phone at 301-500-1556.

This page was last updated on 4/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Gain Therapeutics Stock Forecast, Price & News

Adding

Adding

Adding Gain Therapeutics, Inc.

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Headlines

MarketRank™

Overall MarketRank™

3.5 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage

5.0 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment